| Bortezomib or high-dose dexamethasone for relapsed multiple myeloma PG Richardson, P Sonneveld, MW Schuster, D Irwin, EA Stadtmauer, ... New England journal of medicine 352 (24), 2487-2498, 2005 | 3084 | 2005 |
| Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group International Myeloma Working Group British journal of haematology 121 (5), 749-757, 2003 | 2610 | 2003 |
| Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells R Catlett-Falcone, TH Landowski, MM Oshiro, J Turkson, A Levitzki, ... Immunity 10 (1), 105-115, 1999 | 2122 | 1999 |
| Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. RH Collins Jr, O Shpilberg, WR Drobyski, DL Porter, S Giralt, R Champlin, ... Journal of clinical oncology 15 (2), 433-444, 1997 | 1554 | 1997 |
| Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells T Wang, G Niu, M Kortylewski, L Burdelya, K Shain, S Zhang, ... Nature medicine 10 (1), 48-54, 2004 | 1439 | 2004 |
| Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines JS Damiano, AE Cress, LA Hazlehurst, AA Shtil, WS Dalton Blood, the Journal of the American Society of Hematology 93 (5), 1658-1667, 1999 | 1175 | 1999 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 1006 | 2012 |
| Environment-mediated drug resistance: a major contributor to minimal residual disease MB Meads, RA Gatenby, WS Dalton Nature reviews cancer 9 (9), 665-674, 2009 | 958 | 2009 |
| MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA W Kong, H Yang, L He, J Zhao, D Coppola, WS Dalton, JQ Cheng Molecular and cellular biology 28 (22), 6773-6784, 2008 | 957 | 2008 |
| Overexpression of a Mr 110,000 Vesicular Protein in Non-P-Glycoprotein-mediated Multidrug Resistance RJ Scheper, HJ Broxterman, GL Scheffer, P Kaaijk, WS Dalton, ... Cancer research 53 (7), 1475-1479, 1993 | 834 | 1993 |
| Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. WS Dalton, TM Grogan, PS Meltzer, RJ Scheper, BG Durie, CW Taylor, ... Journal of Clinical Oncology 7 (4), 415-424, 1989 | 696 | 1989 |
| Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial PG Richardson, P Sonneveld, M Schuster, D Irwin, E Stadtmauer, T Facon, ... Blood, The Journal of the American Society of Hematology 110 (10), 3557-3560, 2007 | 682 | 2007 |
| A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma PG Richardson, E Blood, CS Mitsiades, S Jagannath, SR Zeldenrust, ... Blood 108 (10), 3458-3464, 2006 | 645 | 2006 |
| The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance MB Meads, LA Hazlehurst, WS Dalton Clinical Cancer Research 14 (9), 2519-2526, 2008 | 622 | 2008 |
| P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. TP Miller, TM Grogan, WS Dalton, CM Spier, RJ Scheper, SE Salmon Journal of Clinical Oncology 9 (1), 17-24, 1991 | 509 | 1991 |
| Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines DD Ross, W Yang, LV Abruzzo, WS Dalton, E Schneider, H Lage, ... Journal of the National Cancer Institute 91 (5), 429-433, 1999 | 508 | 1999 |
| Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations WT Beck, TM Grogan, CL Willman, C Cordon-Cardo, DM Parham, ... Cancer research 56 (13), 3010-3020, 1996 | 506 | 1996 |
| Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo G Niu, R Heller, R Catlett-Falcone, D Coppola, M Jaroszeski, W Dalton, ... Cancer research 59 (20), 5059-5063, 1999 | 469 | 1999 |
| Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR) LA Hazlehurst, JS Damiano, I Buyuksal, WJ Pledger, WS Dalton Oncogene 19 (38), 4319-4327, 2000 | 463 | 2000 |
| P-glycoprotein expression and function in circulating blood cells from normal volunteers WT Klimecki, BW Futscher, TM Grogan, WS Dalton | 453 | 1994 |
Lori HazlehurstWEST VIRGINIA UNIVVerified email at hsc.wvu.edu
